A Phase I, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0077 as a Single Agent in Patients with Locally Advanced or Metastatic PIK3CA-Mutant Solid Tumors and in Combination with Endocrine and Targeted Therapies in Patients with Locally Advanced or Metastatic PIK3CA Mutant Hormone-Receptor Positive Breast Cancer
A Study for Patients with Locally Advanced or Metastatic Breast Cancer Using Study Drug GDC-0077
Sponsor: Genentech, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR0323
U.S. Govt. ID: NCT03006172
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of the study is to evaluate the safety and side effects of the study drug, GDC-0077. This study also looks for any anti-cancer activity of GDC-0077 alone in participants with locally advanced or metastatic breast cancer in postmenopausal women.
Investigator
Melissa Accordino, MD
Do You Qualify?
Have you been diagnosed with breast cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162